Enliven Therapeutics (NASDAQ:ELVN) Price Target Raised to $67.00

Enliven Therapeutics (NASDAQ:ELVN) had its price objective hoisted by The Goldman Sachs Group from $59.00 to $67.00 in a report released on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other analysts have also recently issued reports on ELVN. Mizuho upped their price objective on Enliven Therapeutics from $45.00 to $62.00 and gave the stock an “outperform” rating in a report on Tuesday, June 2nd. Stifel Nicolaus raised their target price on shares of Enliven Therapeutics from $60.00 to $80.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Guggenheim started coverage on shares of Enliven Therapeutics in a research report on Tuesday, May 12th. They issued a “buy” rating and a $80.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Friday, July 17th. Finally, Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Enliven Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $70.50.

Enliven Therapeutics Stock Down 0.1%

Shares of Enliven Therapeutics stock opened at $52.81 on Tuesday. Enliven Therapeutics has a twelve month low of $14.78 and a twelve month high of $54.88. The business has a 50-day moving average price of $45.26 and a 200-day moving average price of $37.16. The firm has a market cap of $3.22 billion, a price-to-earnings ratio of -31.62 and a beta of 0.24.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. On average, equities analysts expect that Enliven Therapeutics will post -1.57 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $43.80, for a total value of $263,588.40. Following the sale, the chief financial officer owned 51,000 shares of the company’s stock, valued at approximately $2,233,800. This represents a 10.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the firm’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $50.49, for a total transaction of $504,900.00. Following the completion of the sale, the director owned 41,884 shares of the company’s stock, valued at $2,114,723.16. This trade represents a 19.27% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 26,018 shares of company stock valued at $1,113,888. 3.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. KBC Group NV purchased a new stake in Enliven Therapeutics in the 1st quarter worth about $38,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Enliven Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after buying an additional 594 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after buying an additional 930 shares during the last quarter. Los Angeles Capital Management LLC purchased a new stake in shares of Enliven Therapeutics in the fourth quarter worth approximately $83,000. Finally, Quantbot Technologies LP lifted its stake in shares of Enliven Therapeutics by 47.1% during the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after acquiring an additional 1,434 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.